The DOI matches its Crossref record.
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Open accessAbstract
Objective: Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC. Design: In this 8-week, phase II, double-blind, multicentre, randomised study, patients with active UC received placebo or BMS-936557 (10 mg/kg) intravenously every other week. The primary endpoint was the rate of clinical response at Day 57; clinical remission and mucosal healing rates were secondary endpoints. Post hoc analyses evaluated the drug exposure–response relationship and histological improvement. Results: 109 patients were included (BMS-936557: n=55; placebo: n=54). Prespecified primary and secondary endpoints were not met; clinical response rate at Day 57 was 52.7% versus 35.2% for BMS-936557 versus placebo (p=0.083), and clinical remission and mucosal healing rates were 18.2% versus 16.7% (p=1.00) and 41.8% versus 35.2% (p=0.556), respectively. However, higher BMS-936557 steady-state trough concentration (C minss ) was associated with increased clinical response (87.5% vs 37.0% (p<0.001) for patients with C minss 108–235 μg/ml vs placebo) and histological improvements (73.0% vs 41.0%; p=0.004). Infections occurred in 7 (12.7%) BMS-936557-treated patients and 3 (5.8%) placebo-treated patients. 2 (3.6%) BMS-936557 patients discontinued due to adverse events. Conclusions: Anti-IP-10 antibody, BMS-936557, is a potentially effective therapy for moderately-to-severely active UC. Higher drug exposure correlated with increasing clinical response and histological improvement. Further dose–response studies are warranted. Clinical Trial Registration Number: ClinicalTrials.gov NCT00656890 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Atherosclerotic Plaque Healing
Vergallo, R., & Crea, F. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2000317 · Cited by 379
Leukocyte Trafficking to the Small Intestine and Colon
Habtezion, A., Nguyen, L. P., Hadeiba, H., & Butcher, E. C. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.046 · Cited by 315
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Metadata
- Authors
- Mayer, L., Sandborn, W. J., Stepanov, Y., Geboes, K., Hardi, R., Yellin, M., Tao, X., Xu, L. A., Salter-Cid, L., Gujrathi, S., Aranda, R., & Luo, A. Y.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2013-03-05
- Volume
- 63
- Issue
- 3
- Pages
- 442-450
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2169559894
- Cited by
- 188
- References
- 0
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. https://app.cochat.ai/papers/10.1136/gutjnl-2012-303424
- The paper
- Mayer, L., Sandborn, W. J., Stepanov, Y., Geboes, K., Hardi, R., Yellin, M., Tao, X., Xu, L. A., Salter-Cid, L., Gujrathi, S., Aranda, R., & Luo, A. Y. (2014). Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. https://doi.org/10.1136/gutjnl-2012-303424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.